Jild 3 № 2 (2026): Aprel - Iyun
85-96
2026-09-02
Ochiq kirish

Yurak-qon tomir xavfini stratifikatsiya qilishda yallig‘lanish markerlari

David Sh.Asanov
Nurali A.Kurbanov
Jurabek I.Yusupov
Otamurod I.Ganiev
https://doi.org/10.70626/cardiouz-2026-3-%25x

Qabul qilingan: 2026-05-15

Nashr etilgan: 2026-09-02

PDF (ruscha)
Crossmark Crossmark

Annotatsiya

Dolzarbligi. Yallig‘lanish jarayonlari ateroskleroz va yurak-qon tomir kasalliklari (YQTK) patogenezida muhim rol o‘ynaydi. So‘nggi yillarda standart umumiy qon tahlili asosida hisoblanadigan yallig‘lanish indekslaridan yurak-qon tomir xavfini prognozlashda foydalanishga katta e’tibor qaratilmoqda.


Maqsad. Yallig‘lanish markerlari va ularning yurak-qon tomir hodisalarini prognozlashdagi amaliy ahamiyatiga oid zamonaviy ilmiy ma’lumotlarni kompleks tahlil qilish.


Materiallar va usullar. 2012–2025-yillarda davriy ilmiy nashrlarda chop etilgan, kardiologiyada yallig‘lanish markerlarini o‘rganishga bag‘ishlangan maqolalar tahlil qilindi. Manba sifatida elektron kutubxona tizimlaridagi sistematik sharhlar, yirik epidemiologik tadqiqotlar va nazorat qilinadigan klinik sinovlar natijalari, shuningdek Scopus va Web of Science bazalaridagi 40 dan ortiq yuqori iqtibosli tadqiqotlar (2012–2025), jumladan umumiy hisobda 800 000 dan ortiq bemorni qamrab olgan meta-tahlillar olindi.


Natijalar. Bir qator yallig‘lanish ko‘rsatkichlari yurak-qon tomir asoratlarini prognozlashda mustaqil prognostik ahamiyatga ega ekanini ko‘rsatdi. Tizimli immun-yallig‘lanish indeksi (SII) yuqori prognostik qiymat ko‘rsatdi — AUC=0,78; tizimli yallig‘lanish javobi indeksi (SIRI) — AUC=0,82; neytrofillarning limfotsitlarga nisbati (NLR) — AUC=0,75; trombotsitlarning limfotsitlarga nisbati (PLR) — AUC=0,71. Kompleks indekslar alohida markerlarga nisbatan yuqoriroq samaradorlik ko‘rsatdi.


Xulosa. Yallig‘lanish indekslari yurak-qon tomir xavfini stratifikatsiya qilish uchun qulay, iqtisodiy jihatdan samarali va takrorlanuvchan biomarkerlar bo‘lib, an’anaviy xavf omillari va sitokin markerlarini to‘ldiradi. Ularni klinik amaliyotga integratsiya qilish xavfni prognozlash aniqligini oshirish va terapevtik qarorlarni asoslashga yordam berishi mumkin.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843.

  2. Kaptoge S, Di Angelantonio E, Lowe G, et al.; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9732):132-140.

  3. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):55-59.

  4. Angkananard T, Anothaisintawee T, McEvoy M, et al. Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:2703518.

  5. Chen Y, Wang W, Zeng L, et al. Association between Neutrophil-lymphocyte Ratio and All-cause Mortality and Cause-specific Mortality in US Adults, 1999-2014. Int J Gen Med. 2021;14:10203-10211.

  6. Kurtul A, Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review. Angiology. 2019;70(9):802-818.

  7. Zhai G, Wang J, Liu Y, Zhou Y. Platelet-lymphocyte Ratio as a New Predictor of In-hospital Mortality in Cardiac Intensive Care Unit Patients. Sci Rep. 2021;11(1):23578.

  8. Gupta K, Kalra R, Pate M, et al. Relative Predictive Value of Circulating Immune Markers in US Adults without Cardiovascular Disease: Implications for Risk Reclassification. Mayo Clin Proc. 2021;96(7):1812-1821.

  9. Li Q, Ma X, Shao Q, Yang Z, et al. Prognostic Impact of Multiple Lymphocyte-based Inflammatory Indices in Acute Coronary Syndrome Patients. Front Cardiovasc Med. 2022;9:811790.

  10. Yang YL, Wu CH, Hsu PF, et al. Systemic Immune-Inflammation Index (SII) Predicted Clinical Outcome in Patients with Coronary Artery Disease. Eur J Clin Invest. 2020;50(5):e13230.

  11. Saylik F, Akbulut T. Systemic Immune-inflammation Index Predicts Major Cardiovascular Adverse Events in Patients with ST-Segment Elevated Myocardial Infarction. Arq Bras Cardiol. 2022;119(1):14-22.

  12. Li H, Wu X, Bai Y, et al. Physical Activity Attenuates the Associations of Systemic Immune-inflammation Index with Total and Cause-specific Mortality among Middle-aged and Older Populations. Sci Rep. 2021;11(1):12532.

  13. Dziedzic EA, Gasior JS, Tuzimek A, et al. Association of novel inflammatory biomarkers - systemic inflammatory index (SII) and systemic inflammatory response index (SIRI) - with the severity of coronary artery disease. Int J Mol Sci. 2022;23(17):9553.

  14. Han K, Shi D, Yang L, et al. Prognostic Value of Systemic Inflammatory Response Index in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Ann Med. 2022;54(1):1667-1677.

  15. Nascimento MAL, Ferreira LGR, Alves TVG, Rios DRA. Inflammatory Hematological Indices, Cardiovascular Disease and Mortality: A Narrative Review. Arq Bras Cardiol. 2024;121(7):e20230752.

  16. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.

  17. Zhang B, Li XL, Zhao CR, et al. Interleukin-6 as a predictor of the risk of cardiovascular disease: a meta-analysis of prospective epidemiological studies. Immunol Invest. 2018;47(7):689-699.

  18. Fest J, Ruiter R, Ikram MA, et al. Reference Values for White Blood-cell-based Inflammatory Markers in the Rotterdam Study: A Population-based Prospective Cohort Study. Sci Rep. 2018;8(1):10566.

  19. Jin Z, Wu Q, Chen S, et al. The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-cause Mortality: A Ten-year Follow-up Study in 85,154 Individuals. J Inflamm Res. 2021;14:131-140.

  20. Urbanowicz T, Michalak M, et al. Neutrophil Counts, Neutrophil-to-Lymphocyte Ratio, and Systemic Inflammatory Response Index (SIRI) Predict Mortality after Off-Pump Coronary Artery Bypass Surgery. Cells. 2022;11(7):1124.

  21. Wang X, Ni Q, Wang J, et al. Systemic Inflammation Response Index Is a Promising Prognostic Marker in Elderly Patients with Heart Failure: A Retrospective Cohort Study. Front Cardiovasc Med. 2022;9:871031.

  22. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021.

  23. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325.

  24. Ye Z, Hu T, Wang J, et al. Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:933913.

  25. Li W, Wang X, Diao H, et al. Systemic immune inflammation index with all-cause and cause-specific mortality: a meta-analysis. Inflamm Res. 2024;73(12):2199-2216.

  26. Xia Y, Xia C, Wu L, et al. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up study. J Clin Med. 2023;12(3):1128.

  27. Zhao Z, Zhang X, Sun T, et al. Prognostic value of systemic immune-inflammation index in CAD patients: systematic review and meta-analyses. Eur J Clin Invest. 2024;54(2):e14100.

  28. Zhang C, Li M, Liu L, et al. Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord. 2024;24(1):189.

  29. Marchi F, Pylypiv N, Parlanti A, et al. Systemic immune-inflammation index and systemic inflammatory response index as predictors of mortality in ST-elevation myocardial infarction. J Clin Med. 2024;13(5):1256.

  30. Gu L, Xia Z, Qing B, et al. Systemic inflammatory response index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease. Front Immunol. 2024;15:1338025.

  31. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016;14(5):573-577.

  32. Arbel Y, Finkelstein A, Halkin A, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 2012;225(2):456-460.

  33. Agarwal R, Aurora RG, Siswanto BB, et al. The prognostic value of neutrophil-to-lymphocyte ratio across all stages of coronary artery disease. Coron Artery Dis. 2022;33(2):137-143.

  34. Li W, Liu Q, Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci Rep. 2017;7:40426.

  35. Kurtul A, Murat SN, Yarlioglues M, et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol. 2014;114(7):972-978.

  36. Urbanowicz T, Olasinska-Wisniewska A, Michalak M, et al. Impact of neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) and platelet-to-lymphocyte ratio (PLR) on long-term survival in off-pump coronary artery bypass grafting. Biology. 2021;11(1):34.

  37. Meng Z, Yang J, Wu J, Zheng X, Zhao Y, He Y. Association between the platelet-lymphocyte ratio and short-term mortality in patients with non-ST-segment elevation myocardial infarction. Clin Cardiol. 2021;44(7):994-1001.

  38. Yuan M, Ren F, Gao D. The value of SII in predicting the mortality of patients with heart failure. Dis Markers. 2022;2022:3455372.

  39. Li H, Zhou Y, Ma Y, Han S, Zhou L. The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis. Kardiol Pol. 2017;75(7):666-673.

  40. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. 2017;17(4):248-261.

  41. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest. 2013;123(1):27-36.

  42. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-3384.

  43. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709-721.

Mualliflar haqida

David Sh.Asanov
david.asanov.2018@mail.ru
Respublika ixtisoslashtirilgan ilmiy-amaliy tibbiyot kardiologiya markazining Jizzax filiali
https://orcid.org/0000-0002-8723-703X
Nurali A.Kurbanov
yaxyouz@tuit.uz
Respublika ixtisoslashtirilgan ilmiy-amaliy tibbiyot kardiologiya markazining Jizzax filiali
Jurabek I.Yusupov
jorabek9663@gmail.com
Respublika ixtisoslashtirilgan ilmiy-amaliy tibbiyot kardiologiya markazining Jizzax filiali
Otamurod I.Ganiev
otamurodganiyev1996@gmail.com
Respublika ixtisoslashtirilgan ilmiy-amaliy tibbiyot kardiologiya markazining Jizzax filiali

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Yurak-qon tomir xavfini stratifikatsiya qilishda yallig‘lanish markerlari (D. Asanov, N. Kurbanov, J. Yusupov, & O. Ganiev, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(2), 85-96. https://doi.org/10.70626/cardiouz-2026-3-%x
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)